Guggenheim analyst Rohit Vanjani maintained a Hold rating on Revance Therapeutics (NASDAQ: RVNC) today. The company’s shares opened today at $29.
According to TipRanks.com, Vanjani is a 4-star analyst with an average return of 10.6% and a 50.4% success rate. Vanjani covers the Healthcare sector, focusing on stocks such as Sienna Biopharmaceuticals Inc, Endo International, and Foamix Pharma.
Revance Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $49.60.
See today’s analyst top recommended stocks >>
Based on Revance Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $35.91 million. In comparison, last year the company had a GAAP net loss of $27.16 million.
Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RVNC in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Revance Therapeutics, Inc. is a clinical stage biopharmaceutical company. It is engaged in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic, and therapeutic applications.
